tiprankstipranks
Fresenius Medical Care AG & Co. KGaA (DE:FME)
XETRA:FME
Want to see DE:FME full AI Analyst Report?

Fresenius Medical Care AG & Co. KGaA (FME) Price & Analysis

21 Followers

FME Stock Chart & Stats

€38.69
-€0.05(-0.11%)
At close: 4:00 PM EST
€38.69
-€0.05(-0.11%)

Bulls Say, Bears Say

Bulls Say
Free Cash Flow StrengthSustained, sizable operating and free cash flow provides durable internal funding for capex, dividends, and debt reduction. Strong cash conversion (FCF ~65% of net income) improves financial flexibility versus peers and supports strategic investments and resilience through reimbursement cycles.
Integrated Care + Products ModelA vertically integrated model links clinic volumes to recurring consumable and service sales, creating repeatable demand and cross-selling. The installed equipment base and clinic footprint support predictable consumable revenue and aftermarket services, strengthening long-term commercial durability.
Improving LeverageMeaningful reduction in leverage de-risks the balance sheet and lowers refinancing and interest exposure. Improved leverage enhances capacity for strategic M&A, investment in clinics and manufacturing, and provides a stronger foundation to navigate reimbursement and macro headwinds.
Bears Say
Stagnant Revenue TrendA flat-to-slightly-declining top line limits growth optionality and increases reliance on cost cuts or mix shifts to lift earnings. Without durable patient volume growth or improved reimbursement, long-term EPS gains must come from efficiency or pricing power, which can be constrained in healthcare markets.
Moderate, Volatile MarginsRelatively modest and historically volatile margins constrain the company's buffer against cost inflation or reimbursement cuts. Low margins reduce ability to absorb adverse regulatory or supply shocks and make sustained earnings expansion sensitive to operational execution and pricing leverage.
Payor & Regulatory ExposureRevenue and profitability are structurally tied to government and insurer reimbursement rules and regulatory regimes. Changes in payor policy, reimbursement rates, or clinic funding generate lasting revenue pressure and require strategic adaptation, creating persistent external policy risk.

Fresenius Medical Care AG & Co. KGaA News

FME FAQ

What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was €34.57 and its highest was €49.10 in the past 12 months.
    What is Fresenius Medical Care AG & Co. KGaA’s market cap?
    Fresenius Medical Care AG & Co. KGaA’s market cap is €10.86B.
      When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
      Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 04, 2026 which is in 36 days.
        How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
        Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported €0.91 earnings per share for the quarter, missing the consensus estimate of €1.012 by -€0.102.
          Is Fresenius Medical Care AG & Co. KGaA overvalued?
          According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Fresenius Medical Care AG & Co. KGaA pay dividends?
            Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of €1.49 which represents an annual dividend yield of 3.54%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
              What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
              Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.04.
                How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
                Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
                  What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
                  Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, missing expectations of €1.012. Following the earnings report the stock price went down -10.678%.
                    Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
                    Currently, no hedge funds are holding shares in DE:FME
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Fresenius Medical Care AG & Co. KGaA Stock Smart Score

                      Company Description

                      Fresenius Medical Care AG & Co. KGaA

                      Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.

                      Fresenius Medical Care AG & Co. KGaA (FME) Earnings & Revenues

                      FME Stock 12 Month Forecast

                      Average Price Target

                      €38.24
                      ▼(-1.16% Downside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","49":"€49","34.75":"€34.8","39.5":"€39.5","44.25":"€44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.239999999999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€38.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,34.75,39.5,44.25,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.4,37.138461538461534,37.87692307692308,38.61538461538461,39.353846153846156,40.09230769230769,40.83076923076923,41.56923076923077,42.30769230769231,43.04615384615384,43.784615384615385,44.52307692307692,45.261538461538464,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.4,36.54153846153846,36.68307692307692,36.824615384615385,36.966153846153844,37.107692307692304,37.24923076923076,37.39076923076923,37.53230769230769,37.67384615384615,37.81538461538461,37.956923076923076,38.098461538461535,{"y":38.239999999999995,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.4,35.98461538461538,35.56923076923077,35.15384615384615,34.738461538461536,34.323076923076925,33.90769230769231,33.49230769230769,33.07692307692307,32.66153846153846,32.246153846153845,31.83076923076923,31.415384615384614,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.463,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46.924,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.616,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":42.347,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.539,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.77,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.145,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.193,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.635,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.308,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.106,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.126,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.4,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Bayer
                      Carl Zeiss Meditec
                      Merck KGaA
                      Sartorius
                      Siemens Healthineers AG

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks